Allogeneic hematopoietic cell transplantation (allo-HCT) of older or patients with comorbidities has become possible due to new regimens for reduced-intensity conditioning. The use of fludarabine, carmustine and melphalan as the preparative regimen (FBM) reduces toxicity while providing substantial anti-leukemic activity. Chronic GVHD (cGVHD) of the lung or bronchiolitis obliterans syndrome (BOS) remains a serious non-infectious complication contributing to treatment-related morbidity. We conducted a retrospective analysis of 259 patients (median age: 61.5, range: 24-76 years) transplanted after FBM conditioning to identify and characterize clinical risk factors for developing BOS. The cumulative incidence rate of BOS was 4.2% (95% confidence interval (CI): 2.4-7.6%) at 1 year and 8.5% (95% CI: 5.6-12.9%) at 5 years after allo-HCT with a median follow-up of 36.5 (range: 3-136) months. In multivariate analysis, age o55 years at allo-HCT (who received 25% higher carmustin-dose in preparative regimen), pulmonary complications after allo-HCT and GVHD prophylaxis without in-vivo T-cell depletion (cyclosporine-A/ATG or cyclosporine-A/ alemtuzumab) were associated with BOS. We observed no significant differences in clinical variables such as smoking or lung diseases before allo-HCT. In contrast to cGVHD affecting other organs, BOS showed no impact on overall survival. In conclusion, we identified risk factors associated with developing BOS after conditioning with a reduced toxicity protocol.
INTRODUCTION
In recent years new protocols for reduced toxicity/intensity conditioning have allowed allogeneic hematopoietic cell transplantation (allo-HCT) in older patients or patients with comorbidities. The use of fludarabine, carmustin (also known as BCNU) and melphalan (FBM) as preparative regimen confers reduced toxicity with substantial anti-leukemic activity 1 and an adequate quality of life. 2 Nevertheless, chronic GVHD (cGVHD) in general and cGVHD of the lung as a serious non-infectious, late-onset complication contribute to treatment-related morbidity and mortality. 3 Chronic pulmonary GVHD comprises several entities including bronchiolitis obliterans syndrome (BOS), which is defined as new onset of obstructive disease after allo-HCT. Other entities related, but not exclusively, to chronic pulmonary GVHD are less well defined and include bronchiolitis obliterans organizing pneumonia and idiopathic pneumonia syndrome, which both have a different clinical presentation and course. [4] [5] [6] Histologically, BOS is characterized by inflammation and progressive circumferencial fibrosis of small terminal airways. 7 To homogenize the diagnostic and response criteria for clinical trials, the National Institutes of Health (NIH) Consensus Development defined BOS as the new onset of an obstructive pulmonary defect clinically manifested by dyspnea on exertion, cough, or wheezing. Evidence of obstruction and air trapping is revealed in pulmonary function tests (PFTs) and, in the case of air trapping, also via radiological diagnostics. Pulmonary infections should be also excluded by radiography and in microbiological samples. 8 These diagnostic criteria have been recently evaluated and revised. 9 The incidence of BOS in several other publications ranged from 8.3% to 26%. 3, 5, 10, 11 These differences may be attributed to differences in the definition of BOS, conditioning protocol's toxicity, GVHD prophylaxis, hematopoietic stem cell source and HLA compatibility. In this regard, recent data have shown that non-myeloablative conditioning protocols correlate with a decline in the incidence of bronchiolitis obliterans after allo-HCT. 12 Although donor T-cells may mediate cGVHD in general, clinical factors associated with the recruitment and activation of T-cells in the lungs, preventive measurements and successful treatment for BOS have not been addressed in a homogeneously treated cohort of patients. Therefore, we conducted a retrospective analysis at the University Medical Center Freiburg of transplanted patients homogeneously prepared with the FBM conditioning protocol to characterize the incidence of BOS after a reduced-intensity conditioning protocol, to identify clinical risk factors for developing BOS and to analyze outcome variables and response to therapy in patients after developing BOS.
PATIENTS AND METHODS

Patient selection
Between 1 January 1998 and 31 December 2007, 337 patients were conditioned according to the FBM protocol (fludarabine, BCNU, melphalan) and 281 survived more than 100 days, and of those, 259 underwent PFTs for analysis, thereby fulfilling this study's inclusion criteria.
Conditioning regimen, GVHD prophylaxis and stem cell source (ATG-F, Fresenius, Graefelfing, Germany) 13 or alemtuzumab given intravenously on days À 2 and À 1, range: 10-40 mg (Campath, Schering).
14 Allo-HCT was performed from related (103/259, 39.7%) and unrelated donors (156/259, 60.3%). All patients were treated according to institutional transplant guidelines for antimicrobial, antifungal and antiviral prophylaxis.
14 aGVHD and cGVHD was clinically diagnosed on the basis of standard published criteria. 8 aGVHD was graded using the criteria of Przepiorka et al. 15 cGVHD was defined as GVHD occurring 100 days or more after allogeneic HCT and graded as limited or extensive according to Shulman et al. 16 donor lymphocyte infusion (DLI)-induced GvHD was defined as any GVHD after at least one application of DLI. All patients provided informed consent for treatment according to the ethics committee-approved, FBM reduced-intensity conditioning protocol. All data were evaluated as of 30th June 2010.
Pulmonary function tests
Lung function was measured by body plethysmography before allo-HCT and during follow-up following international guidelines. [17] [18] [19] Patients underwent PFTs routinely a week before and 3, 6, 12 and 24 months after allo-HCT, and when clinically indicated. The diagnosis of BOS was defined by NIH criteria: 8 forced expiratory volume in 1 s (FEV1) o75% of predicted value and ratio of FEV in 1 s divided by forced vital capacity (FEV1/FVC) o70%; residual volume 4120% and/or radiological signs in chest CT of air trapping together with the absence of infection. To exclude infections, standard culture and staining methods for bacterial, viral and fungal pathogens were employed. The NIH lung score was calculated following the NIH guidelines. 8 Study endpoints, definitions and statistical analysis Statistical analysis of patient characteristics was conducted using SPSS v. 16 .0 (IBM, New York City, NY, USA), STATA v 11.0 (College Station, TX, USA) and SAS V9.2 (SAS Institute Inc., Cary, NC, USA) software. Overall survival (OS) was defined as time from allo-HCT until death from any cause, and disease-free survival was calculated as time from allo-HCT to death from any cause or relapse, whichever occurred first. For those patients not experiencing the event in question for OS or disease-free survival during follow-up, time to last contact was used as a censored observation. For BOS and cGVHD besides BOS, death without BOS/cGVHD besides BOS were considered as competing risks. Relapse was defined as detection of disease after allo-HCT; death without prior relapse was considered as a competing risk and denoted as non-relapse mortality. We analyzed time to first detection of carbon monoxide diffusion corrected to Hb (DLCOc SB) o60% and o80% of predicted, where death without DLCOc SB o60%/ o80% was considered as competing.
The estimation of cumulative incidence rates for the above-named competing events was conducted using the Aalen Johansen estimator 20 and are presented with two-sided 95% confidence intervals (CI).
Multivariate analyses for time to BOS were conducted using the Cox proportional hazards regression model. Covariates with a univariate Po0.1 were included, cGVHD was used as a time-dependent covariate. Causespecific hazard ratios (HRs) and two-sided 95%CIs of risk factors for developing BOS were estimated. We further applied the Fine and Gray model to compare cumulative incidence rates with respect to age (o55 years or X55 years). 21, 22 The Cox proportional hazards regression model was used to estimate HRs for OS, disease-free survival, cause-specific HRs for relapse incidence, and non-relapse mortality using BOS and cGVHD besides BOS as timedependent covariates
RESULTS
Incidence of BOS in patients transplanted with the FBM protocol
Two hundred and fifty-nine patients were enrolled in this study (median age at allo-HCT of 61.5 (range: 24-76) years) with a median follow-up of 36.5 (range: 3-136) months. Clinical characteristics of the patients and grafts enrolled in this study are shown in Table 1 . Twenty-four patients (9.3%) developed BOS as defined by NIH criteria, 8 with a median time after allo-HCT of 13 (range: 4-102) months. The cumulative incidence rate of BOS reached 4.2% (95% CI: 2.4-7.6%) after 1 year, 8.5% (95% CI: 5.6-12.9%) after 5 years and 11.9% (95% CI: 7.8-18.3%) after 10 years of allo-HCT ( Figure 1 ). The decrease of FEV1 was from initial median 83% (range: 68-110%) to 56% (range: 30-74%) of predicted values at diagnosis of BOS (Supplementary Table 1 ). Four patients showed BOS after DLI treatment offered after mixed chimerism (3/4) and relapse (1/4). One patient developed BOS after treatment with IFN-a therapy given because of mixed chimerism. In one patient, early CyA withdrawal after allo-HCT due to disease progression resulted in the development of BOS.
Association of clinical characteristics with BOS
In univariate Cox-regression analysis for cause-specific hazards, the following clinical characteristics were associated with BOS (Po0.1) and included in the multivariate analysis: patients transplanted with an age o55 years; lymphoid malignancies including ALL, CLL, B-cell non-Hodgkin lymphoma and multiple myeloma; lung disease after allo-HCT including pneumonia, bronchitis and fungal infections; GVHD prophylaxis without in-vivo T-cell depletion; related donor; positive CMV donor status and male donor sex. In contrast, several clinical characteristics were not statistically associated with developing BOS: patient sex, disease remission status, CMV reactivation, HLA-mismatch, acute GVHD, former smoking status or lung disease before allo-HCT (Supplementary Table 2 ).
In the multivariate analysis cGVHD besides BOS was included as hypothesis variable to study the influence of cGVHD on the causespecific HRs of other clinical variables. Following clinical characteristics were identified as being associated with BOS in multivariate analysis via the Cox proportional hazards model following stepwise backward selection: patient age o55 years (P ¼ 0.008, HR: 3.30), lung disease after allo-HCT including pneumonia, bronchitis and fungal infections (P ¼ 0.02, HR: 5.55) and GVHD prophylaxis without in-vivo T-cell depletion (P ¼ 0.09, HR: 2.12) ( Table 2 ).
Incidence and risk factors for overall cGVHD compared with BOS To further characterize BOS among patients with cGVHD, we analyzed their incidences and associated clinical factors. The cumulative incidence of chronic GVHD besides BOS was 47.5% (95% CI: 41.8-54.0%) at 1 year and 52.5% (95% CI: 46.6-59.1%) at 5 years after allo-HCT (Figure 1 ). Among patients with BOS, 17/24 (71%) showed extensive cGVHD and clinically severe grade of cGVHD was observed in 11/24 (46%) patients. Of note, 5/24 (21%) patients with BOS did not show any other organ involvement by cGVHD. Two of these patients were on immunosuppression beyond day 100 after allo-HCT due to aGVHD. Additional two patients developed DLI-induced GVHD and one patient was treated with IFN-a due to mixed chimerism before BOS (Supplementary Table 3 ).
To identify specific risk factors for BOS, which were not generally associated with chronic GVHD, we analyzed clinical factors for developing cGVHD besides BOS in the uni-and multivariate analysis. The following clinical characteristics were associated with cGVHD besides BOS: GVHD prophylaxis without invivo T-cell depletion, lung disease prior and after allo-HCT and acute GVHD (Supplementary Tables 4 and 5 ).
Age as a risk factor for BOS Age under 55 years at the time of allo-HCT was identified as a specific risk factor for BOS, which was not associated with cGVHD besides BOS. We hypothesized that in this particular group of patients, in addition to several prior lines of chemotherapy with putative pulmonary and overall toxicity, resulting in the clinical decision to apply reduced-intensity conditioning instead of a myeloablative protocol, higher doses of carmustine may be causing critical lung toxicity. Carbon monoxide diffusion changes have been established as an indirect indicator of lung damage caused by chemotherapeutics including carmustine. 23 DLCOc SB changes were analyzed by cumulative incidence rates. Younger patients who received 2 Â 200 mg/m 2 carmustine in the conditioning protocol before allo-HCT developed carbon monoxide diffusion abnormalities, as shown by a significantly higher cumulative incidence of DLCOc SB below 60% (SHR: 2.32, P ¼ 0.001) and below 80% of predicted values (SHR: 1.46, P ¼ 0.049) (Supplementary Table 6 ). Of note, the prevalence of DLCOc SB abnormalities and the values for FEV1 and FEV1/FVC ratio before allo-HCT were not different between both age groups (data not shown).
Outcome in patients with BOS and chronic GVHD OS, disease-free survival, relapse incidence and non-relapse mortality were analyzed by Cox proportional hazards model using BOS and cGVHD besides BOS as time-dependent covariates ( Table 3 ). Development of BOS had no impact on these outcome parameters. In contrast, patients who developed cGVHD besides BOS showed an improved overall survival (P ¼ 0.06, HR: 0.72).
We analyzed retrospectively the impact of immunosuppression at the time of BOS diagnosis and after BOS diagnosis on improvement of FEV1 values. Due to the small number of patients, we did not observe any trend for FEV1 improvement with a specific therapy (Supplementary Table 7 ).
Seven out of 11 patients with BOS died from pulmonary causes, especially pneumonia (fungal, bacterial, CMV, tuberculosis and after aspiration), suggesting that prolonged or high doses of immunosuppression during BOS treatment may induce lung complications resulting in increased morbidity and mortality (data not shown).
DISCUSSION
BOS is a late-onset complication of allo-HCT. Its clinical presentation with cough, dyspnea and/or wheezing requires a wide differential diagnosis including infections, lung toxicity and GVHD. The clinical diagnosis is based on PFTs, radiological chest images and the exclusion of infection. When BOS is diagnosed, the histological changes are often irreversible and therapy is oriented to symptomatic treatment. Thus, BOS contributes substantially to patient morbidity after allo-HCT.
Several risk factors were identified in our cohort of patients transplanted according to a reduced conditioning protocol. Younger patients aged o55 years at the time of allo-HCT had a higher risk for developing BOS. Fifteen out of 68 patients (22.1%) in this age group developed BOS. According to the FBM protocol (patients X55 years: 2 Â 150 mg/m 2 , o55 years: 2 Â 200 mg/m 2 ), younger patients received 25% more BCNU, a well-known cause of lung damage. Of note, patients in this age group showed an increase of DLCOc SB abnormalities, which has been related to lung toxicity by chemotherapy. 23 Although we cannot exclude from our data that subclinical BOS also contributes to diffusion abnormalities, the higher incidence of patients with DLCOc SB BOS, n (%) 24 ( Bronchiolitis obliterans after reduced conditioning J Duque-Afonso et al o60% of predicted at 1 year (patients o55 years: 40.1% vs X55 years: 18.5%) suggests that lung damage by toxicity might precede BOS. The younger patients, which underwent allo-HCT after reduced conditioning protocol, had been treated with several other pulmonary toxic chemotherapeutics or had a reduced performance status before allo-HCT, which might also contribute to BOS. Pulmonary complications including infections after allo-HCT were also associated with the development of BOS in uni-and multivariate analysis. In our cohort of patients, 87% of those who developed BOS had suffered from a pulmonary infection including bacterial and fungal pneumonia, and viral bronchitis/upper respiratory tract infection before BOS diagnosis. The spectra of pulmonary infections in patients with BOS compared with those without BOS were similar, although bacterial pneumonia (48 vs 40%) and bronchitis/upper respiratory tract infection (28 vs 10%) occurred more often in patients with BOS. Chien et al. 24 proposed that respiratory viral infection within the first 100 days after allogeneic HCT is a risk factor for developing BOS. Their data were validated in an independent cohort of patients. 25 Of note, 83% of patients within our cohort developed lung complications including infections after development of BOS, suggesting that BOS and its associated immunosuppression may be risk factors for other lung diseases.
In the multivariate analysis after backward selection, GVHD prophylaxis based on in-vivo T-cell depletion, including ATG and alemtuzumab, showed a beneficial effect on reducing the incidence of BOS, most likely due to lowering of overall incidence of cGVHD. It is postulated that T cells mediate aGVHD. 7, 26 In contrast, the T-cell mediation of cGVHD, including BOS, is more controversial. Nevertheless, in multicentre, randomized trials, the use of ATG as GVHD prophylaxis for allo-HCT from matched, unrelated donors reduced significantly the incidence of cGVHD 13 and BOS, 27 while ex vivo T-cell depletion of stem cell grafts failed to lower the incidence of cGVHD. 28 In a retrospective study in 82 patients undergoing allo-HCT using T-cell depletion (in vivo by administration of the monoclonal anti-CD52 Ab alemtuzumab or ex vivo by CD34-positive selection) of related donor grafts, no patient developed BOS, whereas 8.1% of patients in the control group did. 29 The effect of in-vivo T-cell depletion on lung function is consistent with recently published data by Milano et al. 27 , who showed a protective effect of GVHD prophylaxis with ATG on FEV1/FVC ratio at 1 year after allo-HCT. The protective effect of ATG on chronic lung dysfunction has been demonstrated in prospective randomized trials. 30, 31 Other authors have reported an association of extensive cGVHD with BOS. 3, 32 However, cGVHD besides BOS and aGVHD, both of which were previously identified as a risk factors for BOS in heterogeneous groups of transplanted patients, 3, 33 could not be shown to be significantly associated with BOS in our patient cohort.
Surprisingly, neither former smoker status nor lung diseases before HCT, that is, chronic obstructive pulmonary disease, were associated with BOS, suggesting that BOS is triggered by immunological processes after allo-HCT and that the initial lung condition does not predict the development of BOS. It is also possible that heavy smokers and patients with advanced chronic obstructive pulmonary disease were negatively selected for allo-HCT.
This study has revealed that not BOS, but rather chronic GVHD had a statistical impact on overall survival. Sakaida et al. 3 described the association between late-onset, non-infectious pulmonary complications, including BOS with chronic extensive GVHD and lower relapse incidence but not with overall survival. Several studies 10, 11, 24 showed the negative impact of BOS on outcome variables. We hypothesize that frequently routine PFTs may improve clinical outcome detecting less severe BOS, which may respond to immunosuppressive therapy. In contrast, BOS may counteract the favorable impact of cGVHD on outcome by increasing morbidity, in particular pulmonary complications, and subsequent mortality. Seven out of 11 patients who developed BOS died of pulmonary complications, particularly pneumonia. All cases of non-relapse mortality occurred in the group of patients on immunosuppression before BOS was diagnosed, suggesting that uncontrolled cGVHD requiring escalation or maintenance of immunosuppressive therapy may result in death from pulmonary causes, especially respiratory failure due to infections.
Our study has some limitations to be considered. First, our data were collected retrospectively. Prospective studies are needed to advance in this field, due to the difficulty of diagnosing BOS and interpretation of the clinical data. Second, we focused exclusively Figure 1 . Cumulative incidence of bronchiolitis obliterans syndrome and chronic GVHD after reduced toxicity conditioning. Diagram representing the cumulative incidence rate estimation of BOS and cGVHD besides BOS in the studied patient cohort. Patients with limited and extensive cGVHD were included. on patients with obstructive disease after allo-HCT. Future directions should address non-obstructive pulmonary diseases in the context of cGVHD. Third, younger patients received higher dose of BCNU in our conditioning protocol, which may be a confounding variable.
In conclusion, we detected several risk factors associated with developing BOS in allo-HCT after conditioning with a reduced toxicity protocol (FBM) in the largest cohort investigated so far. These findings might help us to identify a risk population after reduced-intensity conditioning and lead to personalized measures for GVHD prophylaxis and therapy as proposed. 
